COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES
The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
1 .- 48 . (canceled)
49 . A method for preventing or treating at least one side-effect associated with cannabinoid consumption in a human subject in need thereof, comprising
administering to the subject a therapeutically-effective amount of a pharmaceutical composition to prevent or treat the at least one side-effect,
wherein the composition comprises at least one phyto-cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof,
wherein the at least one phyto-cannabinoid and the at least one N-acylethanolamine are present in the composition in a molar ratio of about 1:0.2 to about 1:2000, and
wherein the at least one phyto-cannabinoid is tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), a salt thereof, or any combination thereof.
50 . The method of claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.2 to about 1:5.
51 . The method of claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:1 to about 1:50.
52 . The method of claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:15 to about 1:1800.
53 . The method of claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:25 to about 1:450.
54 . The method of claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:50 to about 1:100.
55 . The method of claim 49 , wherein the at least one phyto-cannabinoid is CBD or a salt thereof.
56 . The method of claim 49 , wherein the pharmaceutical composition comprises about 50-1800 mg of the N-acylethanolamine or salt thereof.
57 . The method of claim 56 , wherein the pharmaceutical composition comprises about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of the N-acylethanolamine or salt thereof.
58 . The method of claim 49 , wherein the at least one N-acylethanolamine is N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof.
59 . The method of claim 58 , wherein the at least one N-acylethanolamine is PEA or a salt thereof.
60 . The method of claim 49 , wherein the pharmaceutical composition comprises CBD or a salt thereof, and PEA or a salt thereof.
61 . The method of claim 49 , wherein the pharmaceutical composition comprises about 0.5-10 mg of the phyto-cannabinoid or salt thereof, and about 200-1800 mg of PEA or a salt thereof.
62 . The method of claim 49 , wherein the pharmaceutical composition comprises about 2.5-10 mg of the phyto-cannabinoid or salt thereof and about 250-1000 mg of PEA or a salt thereof.
63 . The method of claim 49 , wherein the pharmaceutical composition comprises about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg of the phyto-cannabinoid or salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg of PEA or a salt thereof.
64 . The method of claim 49 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration.
65 . The method of claim 49 , wherein the administration of the at least one phyto-cannabinoid and the N-acylethanolamine is repeated.
66 . The method of claim 49 , wherein the at least one side-effect associated with cannabinoid consumption is increased appetite or body-weight gain.
67 . The method of claim 49 , wherein the at least one side-effect associated with cannabinoid consumption is confusion or disorientation.
68 . The method of claim 49 , wherein the at least one side-effect associated with cannabinoid consumption is anxiety.